drugset / Trial / NCT02582749
Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases
Phase 2
Terminated
16 enrolled
Ajjai Alva, MD
Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma · collabHoosier Cancer Research Network · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
Newly diagnosed metastatic prostate cancer subjects with bone metastases will be accrued to this stratified randomized 2-arm Phase II trial. Subjects will be randomized 1:2 to ADT or ADT with Radium-223 dichloride respectively.
Timeline
- Start
- 2016-04
- Primary completion
- 2017-09-14
- Completion
- 2017-09-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Radium-223 dichloride | Other / unclassified | 0.05 mbq/kg | Intravenous |
| Background | Bicalutamide | Other / unclassified | 50 mg | Oral |
| Background | Degarelix | Other / unclassified | — | — |
| Background | Goserelin | Other / unclassified | — | — |
| Background | Leuprolide | Other / unclassified | — | — |